We place the innovation-driven development strategy at a strategic position. To advance the strategy, we consistently strengthen technological innovation, promote the R&D of rare diseases, and establish the full-process product quality management system. We aim to provide premium drugs for our customers, benefit people from the primary level with more medical resources and services, communicate the healthy living idea to communities and citizens, and eventually vitalize the industry and contribute to the Healthy China Initiative.

n Our Performance

l In 2024,spending on scientific R&D RMB 828 million

l In 2024, number of R&D staff 542，proportion of researchers 1.9%

l In 2024, Nearly 90 research platforms at various levels

l In 2024, over 200 ongoing project

l 6 subsidiaries were recognized as "Single industry Champion Enterprises of Guangdong Manufacturing industry".

l 4 subsidiaries were recognized as "Provincial-level small and Medium Enterprises that Use Specialized and Sophisticated Technologies to Produce Novel and Unique Products".

l 3 subsidiaries were recognized as “High-tech Enterprises'

l In 2024, applications for invention patents 104, applications for utility mode 34, invention patents authorized 78，utility model patents authorized 18.

l Cai Zhi Lin’s Traditional Chinese Medicine Culture Museum was awarded “Guangdong Science Popularization and Education Base”.

l The "Integrated Innovation of Traditional Chinese Medicine Quality Testing Technologies and Creation and Application of Support Systems" project, led by HWBYS, was awarded the Second Prize of 2023 National Science and Technology Progress Award.

l The "Key Technological Breakthroughs and Industrial Innovation in Male Health Treatment Drugs" project, led by Baiyunshan General Factory, was awarded the Second Prize of Guangdong Science and Technology Progress Award.

l The "Key Technology Research and Application Demonstration for Cultivating Advantageous Varieties of Characteristic Zhuang Medicine Preparations" of Guangxi Ying Kang wins the first prize of the 2024 Science and Technology Award of the China Medical Association of Minorities.

l The “Amino Thioacetamide Cephalosporins Substituted with C3 Methylene Nitrogen-containing Heterocycles, Its Preparation Approaches and Application” of Chemical Pharmaceutical Factory, "A Macrocyclic Kinase Inhibitor" jointly developed by GYBYS andBaiyunshan General Factory, The "Partially Dissolved Bu Pi Yi Chang Pills and Its Preparation Approaches" of Chen Li Ji,The “Convenient Feeding, Cutting and Drying Integrated Equipment for Chinese medicinal materials” of Wang Lao Ji,wins the 25th China Patent Excellence Award.

n Our Approach to Access to Health Care

To leverage the leading role of technological innovation, we continuously increase input into our research, and have developed a sound technological innovation management system. We integrate resources to advance drug R&D, and in the meantime strictly abide by the ethics of medical science and technology. While enhancing effort in technological innovation, we are also optimizing intellectual property management, thus producing more effective and safer medical products to the people for the sake of their health.

Product quality is the foundation of an enterprise. We continuously strengthen our full lifecycle quality management system covering drug R&D, manufacturing, sales, and use. We continue to optimize the pharmacovigilance system, engage in industry exchanges and collaborations, and achieve mutual benefits in terms of resources, contributing to joint development. Our efforts are focused on ensuring product quality and safety, creating high-quality and reliable products for patients, and dedicating to the development of the industry.

We are committed to bringing high-quality medical resources and services to the primary level, promoting preferential healthcare, and communicating healthy living ideas and habits to the public, thus improving the overall quality of life and well-being.

n Our Stories